Online inquiry

IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4348MR)

This product GTTS-WQ4348MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL5RA gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000564.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3568
UniProt ID Q01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4348MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6122MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ5159MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ1250MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ14340MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ5531MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ5985MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ1454MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ960MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW